These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 20879979)

  • 1. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
    Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
    Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
    Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
    Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.
    Li Y; Parks GD
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29693588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
    Cinci M; Mamidi S; Li W; Fehring V; Kirschfink M
    Target Oncol; 2015 Sep; 10(3):405-13. PubMed ID: 25395366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis.
    Tang G; Pan L; Wang Z; Zhu H; Yang Y; Wang Z; Yue H; Shi Y; Wu D; Jiang Z; Jiang D
    Int Immunopharmacol; 2023 Jan; 114():109450. PubMed ID: 36446233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
    Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
    Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shear stress-mediated changes in the expression of complement regulatory protein CD59 on human endothelial progenitor cells by ECM-integrinα
    Cui X; Zhang X; Bu H; Liu N; Li H; Guan X; Yan H; Wang Y; Zhang H; Ding Y; Cheng M
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):416-421. PubMed ID: 28943429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
    Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
    Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.